Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes

Diabetes Care

Volumn 38, Issue 7, 2015, Pages 1189-1196

  Eckel, Robert H ^a   Henry, Robert R ^b,c   Yue, Patrick ^d   Dhalla, Arvinder ^e   Wong, Pamela ^d   Jochelson, Philip ^d   Belardinelli, Luiz ^d,e   Skyler, Jay S ^f  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GILEAD SCIENCES   (United States)

^e Gilead Sciences   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; RANOLAZINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART DISEASE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSIENT ISCHEMIC ATTACK; TREATMENT WITHDRAWAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANOLAZINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944356404     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2629     Document Type: Article

References (28)

1. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol 2005;96:363-365
2. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038
3. Herlitz J, Wognsen GB, Karlson BW, et al. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis 2000;11:339-346
4. Duarte R, Castela S, Reis RP, et al. Acute coronary syndrome in a diabetic population-risk factors and clinical and angiographic characteristics. Rev Port Cardiol 2003;22:1077-1088
5. Chaitman BR, Pepine CJ, Parker JO, et al, .; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309-316
6. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 2006;8:A10-A13
7. Chaitman BR, Skettino SL, Parker JO, et al, .; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-1382
8. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-575
9. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42-48
10. Morrow DA, Scirica BM, Chaitman BR, et al, .; MERLIN-TIMI 36 Investigators. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-2039
11. Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010;33:1163-1168
12. Ning Y, Zhen W, Fu Z, et al. Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice. J Pharmacol Exp Ther 2011;337:50-58
13. Dhalla AK, Yang M, Ning Y, et al. Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects. Diabetes 2014;63:3545-3556
14. Matsuda M, Defronzo RA, Glass L, et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 2002;51:1111-1119
15. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007;50:797-805
16. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395
17. Ranexa (ranolazine) extended-release tablets. U.S. prescribing information. Foster city, CA, Gilead Sciences, Inc., December 2013
18. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-1532
19. Centers for Disease Control and Prevention (CDC). Prevalence of self-reported cardiovascular disease among persons aged > or =35 years with diabetes - United States, 1997-2005. MMWR Morb Mortal Wkly Rep 2007;56:1129-1132
20. Wong ND, Hui G. Angina prevalence and characteristics in coronary artery disease patients with and without diabetes. J Am Coll Cardiol 2014;63:A1538
21. Rizos CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014;6:517-530
22. Bakris G, Stockert J, Molitch M, et al, .; STAR Investigators. Risk factor assessment for new onset diabetes: literature review. Diabetes Obes Metab 2009;11:177-187
23. Green JB. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. Postgrad Med 2014;126:190-204
24. Kosiborod M, Arnold SV, Spertus JA, et al. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol 2013;61:2038-2045
25. Williamson C, Glauser TA, Burton BS, Schneider D, Dubois AM, Patel D. Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices. Postgrad Med 2014;126:145-160
26. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003;284:E671-E678
27. Lee Y, Berglund ED, Yu X, et al. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. Proc Natl Acad Sci USA 2014;111:13217-13222
28. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al, .; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-1783